Entire Portfolio
Composition of the portfolio as of March 31, 2013
| Celgene | 15.3% | |
| Actelion | 12.0% | |
| Gilead | 11.2% | |
| Isis Pharmaceuticals | 7.6% | |
| Incyte | 7.2% | |
| Vertex Pharmaceuticals | 5.4% | |
| Novo Nordisk | 4.5% | |
| Alexion Pharmaceuticals | 3.8% | |
| Medivation | 3.4% | |
| Immunogen | 3.2% | |
| Ariad Pharmaceuticals | 3.0% | |
| Onyx Pharmaceuticals | 2.8% | |
| Swedish Orphan Biovitrum | 2.5% | |
| The Medicines Company | 1.9% | |
| Halozyme Therapeutics | 1.9% | |
| Glenmark Pharmaceuticals | 1.7% | |
| Endocyte | 1.7% | |
| BioMarin Pharmaceutical | 1.5% | |
| Theravance | 1.2% | |
| Lupin | 1.2% | |
| Bavarian Nordic | 1.2% | |
| Ipca Laboratories | 1.1% | |
| Optimer Pharmaceuticals | 1.0% | |
| Achillion Pharmaceuticals | 0.9% | |
| Probiodrug 1) | 0.8% | |
| Radius Health 1) | 0.6% | |
| Strides Arcolab | 0.5% | |
| Dendreon | 0.3% | |
| Intercell | 0.3% | |
| Idenix Pharmaceuticals | 0.3% | |
| Total securities | CHF 1 633.1 mn | |
| Other assets | CHF 46.8 mn | |
| Other payables | CHF (140.8) mn | |
| Total shareholder’s equity | CHF 1 539.1 mn | |
| Treasury shares (in % of company) 2) | 12.8% |
1) Unlisted company
2) Correspond to the total of all own shares held including the second trading line
News
11.01.2013
11.12.2012